XML 20 R6.htm IDEA: XBRL DOCUMENT v3.21.2
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Common stock
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Accumulated Other Comprehensive Income (Loss) [Member]
Treasury Stock [Member]
Total Amphastar Stockholders' Equity [Member]
Non-controlling Interest [Member]
Total
Balance at Dec. 31, 2019 $ 5 $ 367,305 $ 116,370 $ (4,687) $ (97,627) $ 381,366 $ 46,162  
Balance at Dec. 31, 2019               $ 427,528
Balance at Dec. 31, 2019 52,495,483       (5,918,515)      
Changes in Stockholders' Equity                
Net income (loss) attributable to Amphastar Pharmaceuticals, Inc.     3,949     3,949   3,949
Other comprehensive income (loss) attributable to Amphastar Pharmaceuticals, Inc.       (774)   (774)   (774)
Net income (loss) attributable to non-controlling interest             (424) (424)
Purchase of treasury stock         $ (10,950) (10,950)   (10,950)
Purchase of treasury stock (in shares)         (647,246)      
Issuance of treasury stock in connection with the Company's equity plans   (84)     $ 84      
Issuance of treasury stock in connection with the Company's equity plans (in Shares)         6,873      
Issuance of common stock in connection with the Company's equity plans   (1,238)       (1,238)   (1,238)
Issuance of common stock in connection with the Company's equity plans (in Shares) 369,508              
Share-based compensation expense   5,161       5,161 121 5,282
Balance at Mar. 31, 2020 $ 5 371,144 120,319 (5,461) $ (108,493) 377,514 45,859  
Balance at Mar. 31, 2020               423,373
Balance at Mar. 31, 2020 52,864,991       (6,558,888)      
Balance at Dec. 31, 2019 $ 5 367,305 116,370 (4,687) $ (97,627) 381,366 46,162  
Balance at Dec. 31, 2019               427,528
Balance at Dec. 31, 2019 52,495,483       (5,918,515)      
Changes in Stockholders' Equity                
Net income (loss) attributable to Amphastar Pharmaceuticals, Inc.               7,676
Other comprehensive income (loss) attributable to Amphastar Pharmaceuticals, Inc.               209
Balance at Sep. 30, 2020 $ 5 404,084 124,046 (4,478) $ (118,425) 405,232   450,962
Balance at Sep. 30, 2020             45,730  
Balance at Sep. 30, 2020 54,623,837       (7,089,622)      
Balance at Mar. 31, 2020 $ 5 371,144 120,319 (5,461) $ (108,493) 377,514 45,859  
Balance at Mar. 31, 2020               423,373
Balance at Mar. 31, 2020 52,864,991       (6,558,888)      
Changes in Stockholders' Equity                
Net income (loss) attributable to Amphastar Pharmaceuticals, Inc.     (192)     (192)   (192)
Other comprehensive income (loss) attributable to Amphastar Pharmaceuticals, Inc.       288   288   288
Net income (loss) attributable to non-controlling interest             (1,237) (1,237)
Purchase of treasury stock         $ (5,756) (5,756)   (5,756)
Purchase of treasury stock (in shares)         (329,391)      
Issuance of treasury stock in connection with the Company's equity plans   (130)     $ 130      
Issuance of treasury stock in connection with the Company's equity plans (in Shares)         10,913      
Issuance of common stock in connection with the Company's equity plans   19,448       19,448   19,448
Issuance of common stock in connection with the Company's equity plans (in Shares) 1,507,284              
Share-based compensation expense   6,379       6,379 134 6,513
Balance at Jun. 30, 2020 $ 5 396,841 120,127 (5,173) $ (114,119) 397,681 44,756  
Balance at Jun. 30, 2020               442,437
Balance at Jun. 30, 2020 54,372,275       (6,877,366)      
Changes in Stockholders' Equity                
Net income (loss) attributable to Amphastar Pharmaceuticals, Inc.     3,919     3,919   3,919
Other comprehensive income (loss) attributable to Amphastar Pharmaceuticals, Inc.       695   695   695
ANP Restructuring             (106) (106)
Net income (loss) attributable to non-controlling interest             874 874
Purchase of treasury stock         $ (4,329) (4,329)   (4,329)
Purchase of treasury stock (in shares)         (214,256)      
Issuance of treasury stock in connection with the Company's equity plans   (23)     $ 23      
Issuance of treasury stock in connection with the Company's equity plans (in Shares)         2,000      
Issuance of common stock in connection with the Company's equity plans   3,102       3,102   3,102
Issuance of common stock in connection with the Company's equity plans (in Shares) 251,562              
Share-based compensation expense   4,164       4,164 206 4,370
Balance at Sep. 30, 2020 $ 5 404,084 124,046 (4,478) $ (118,425) 405,232   450,962
Balance at Sep. 30, 2020             45,730  
Balance at Sep. 30, 2020 54,623,837       (7,089,622)      
Balance at Dec. 31, 2020 $ 5 410,061 117,773 (3,721) $ (121,812) 402,306 46,417 402,306
Balance at Dec. 31, 2020               $ 448,723
Balance at Dec. 31, 2020 54,760,922       (7,265,483)     47,495,439
Changes in Stockholders' Equity                
Net income (loss) attributable to Amphastar Pharmaceuticals, Inc.     5,041     5,041   $ 5,041
Other comprehensive income (loss) attributable to Amphastar Pharmaceuticals, Inc.       (1,921)   (1,921)   (1,921)
Net income (loss) attributable to non-controlling interest             (1,082) (1,082)
Purchase of treasury stock         $ (3,783) (3,783)   (3,783)
Purchase of treasury stock (in shares)         (204,698)      
Issuance of treasury stock in connection with the Company's equity plans   (49)     $ 49      
Issuance of treasury stock in connection with the Company's equity plans (in Shares)         4,184      
Issuance of common stock in connection with the Company's equity plans $ 1 (853)       (852)   (852)
Issuance of common stock in connection with the Company's equity plans (in Shares) 423,078              
Share-based compensation expense   4,767       4,767 67 4,834
Balance at Mar. 31, 2021 $ 6 413,926 122,814 (5,642) $ (125,546) 405,558 45,402  
Balance at Mar. 31, 2021               450,960
Balance at Mar. 31, 2021 55,184,000       (7,465,997)      
Balance at Dec. 31, 2020 $ 5 410,061 117,773 (3,721) $ (121,812) 402,306 46,417 402,306
Balance at Dec. 31, 2020               $ 448,723
Balance at Dec. 31, 2020 54,760,922       (7,265,483)     47,495,439
Changes in Stockholders' Equity                
Net income (loss) attributable to Amphastar Pharmaceuticals, Inc.               $ 42,356
Other comprehensive income (loss) attributable to Amphastar Pharmaceuticals, Inc.               (2,556)
Balance at Sep. 30, 2021 $ 6 412,917 160,577 (6,277) $ (137,047) 430,176   430,176
Balance at Sep. 30, 2021               $ 430,176
Balance at Sep. 30, 2021 56,051,622       (8,068,972)     47,982,690
Balance at Mar. 31, 2021 $ 6 413,926 122,814 (5,642) $ (125,546) 405,558 45,402  
Balance at Mar. 31, 2021               $ 450,960
Balance at Mar. 31, 2021 55,184,000       (7,465,997)      
Changes in Stockholders' Equity                
Net income (loss) attributable to Amphastar Pharmaceuticals, Inc.     7,767     7,767   7,767
Other comprehensive income (loss) attributable to Amphastar Pharmaceuticals, Inc.       711   711   711
Net income (loss) attributable to non-controlling interest             855 855
Purchase of treasury stock         $ (5,560) (5,560)   (5,560)
Purchase of treasury stock (in shares)         (298,727)      
Issuance of treasury stock in connection with the Company's equity plans   (142)     $ 142      
Issuance of treasury stock in connection with the Company's equity plans (in Shares)         12,064      
Issuance of common stock in connection with the Company's equity plans   7,247       7,247   7,247
Issuance of common stock in connection with the Company's equity plans (in Shares) 552,209              
Share-based compensation expense   6,270       6,270 (1,027) 5,243
Balance at Jun. 30, 2021 $ 6 427,301 130,581 (4,931) $ (130,964) 421,993 45,230  
Balance at Jun. 30, 2021               467,223
Balance at Jun. 30, 2021 55,736,209       (7,752,660)      
Changes in Stockholders' Equity                
Net income (loss) attributable to Amphastar Pharmaceuticals, Inc.     29,548     29,548   29,548
Other comprehensive income (loss) attributable to Amphastar Pharmaceuticals, Inc.               (1,346)
Other comprehensive income (loss) attributable to Amphastar Pharmaceuticals, Inc.       (984)   (984)   (984)
ANP Restructuring   (22,162) 448 (362)   (22,076) (46,642) (68,718)
Net income (loss) attributable to non-controlling interest             $ 1,412 1,412
Purchase of treasury stock         $ (6,094) (6,094)   (6,094)
Purchase of treasury stock (in shares)         (317,212)      
Issuance of treasury stock in connection with the Company's equity plans   (11)     $ 11      
Issuance of treasury stock in connection with the Company's equity plans (in Shares)         900      
Issuance of common stock in connection with the Company's equity plans   3,869       3,869   3,869
Issuance of common stock in connection with the Company's equity plans (in Shares) 315,413              
Share-based compensation expense   3,920       3,920   3,920
Balance at Sep. 30, 2021 $ 6 $ 412,917 $ 160,577 $ (6,277) $ (137,047) $ 430,176   430,176
Balance at Sep. 30, 2021               $ 430,176
Balance at Sep. 30, 2021 56,051,622       (8,068,972)     47,982,690